Lasting response by vertical inhibition with cetuximab and trametinib in KRAS-mutated colorectal cancer patient-derived xenografts.

导出 OA

翻译打印收藏纠错

作者： Timm M,Reissig ^[1] ; Swetlana,Ladigan-Badura ^[2] ; Anja,Steinberg ^[3] ; Abdelouahid,Maghnouj ^[1] ; Ting,Li ^[4] ; Berlinda,Verdoodt ^[1] ; Sven T,Liffers ^[1] ; Michael,Pohl ^[1] ; Heiner,Wolters ^[5] ; Christian,Teschendorf ^[3] ; Richard,Viebahn ^[5] ; Jakob,Admard ^[4] ; Nicolas,Casadei ^[6] ; Andrea,Tannapfel ^[6] ; Wolff,Schmiegel ^[7] ; Stephan A,Hahn ^[8] ; Deepak B,Vangala ^[8]

作者单位： Department of Molecular GI Oncology, Faculty of Medicine, Ruhr-University Bochum, Germany. ^[1] Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Germany. ^[2] Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany. ^[3] Center for Hemato-Oncological Diseases, University Hospital Knappschaftskrankenhaus, Ruhr-University Bochum, Germany. ^[4] Institute of Pathology, Ruhr University Bochum, Germany. ^[5] Department of Visceral and General Surgery, St. Josef Hospital, Dortmund, Germany. ^[6] Department of Visceral and General Surgery, University Hospital Knappschaftskrankenhaus, Ruhr-University Bochum, Germany. ^[7] Institute of Medical Genetics and Applied Genomics, University of Tübingen, Germany. ^[8]

关键词 CRC EGFR MEK PDX resistance targeted therapy

主题词人类(Humans);抗肿瘤药(Antineoplastic Agents);原癌基因蛋白质类p21(ras)(Proto-Oncogene Proteins p21(ras));结直肠肿瘤(Colorectal Neoplasms);丝裂原激活蛋白激酶激酶类(Mitogen-Activated Protein Kinase Kinases);突变(Mutation)

DOI 10.1002/1878-0261.13510

PMID 37604687

发布时间 2023-11-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交